USPTO Publishes A1 Application for Mucoadhesive Polymeric Prodrug Delivery System
Summary
The USPTO published application US20260108615A1 on April 23, 2026, covering a mucoadhesive polymeric prodrug system using partially succinated polyvinyl alcohol (PVA-SA) that self-assembles into 50–260 nm particles for controlled drug delivery. The prodrug forms ester and/or amide linkages with biologically active compounds including doxorubicin (DOX), cysteamine (CYS), ketoprofen (KETO), and 4-hydroxybenzyl alcohol (HBA), enabling adjustable drug release and improved mucoadhesive properties. The application (No. 18697611) was originally filed on September 29, 2022, by inventors Abdelghafour, Szabó, Janovák, Dékány, and Rovó.
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
The USPTO published application US20260108615A1 discloses a self-assembled mucoadhesive biopolymer particle release system based on partially succinated polyvinyl alcohol (PVA-SA). The polymer contains both hydroxyl and carboxyl pendant groups that form ester and/or amide linkages with amino, carboxyl, and hydroxyl groups of active compounds such as doxorubicin, cysteamine, ketoprofen, and 4-hydroxybenzyl alcohol. The simultaneous hydroxyl and carboxyl groups enable the macromolecules to self-assemble into 50–260 nm nanoparticles, prolonging and regulating drug release.
For parties in the pharmaceutical and drug delivery sector, this published application marks the entry of a novel mucoadhesive prodrug platform into the public patent record, with potential implications for formulation strategies in antitumor, anti-fibrotic, and anti-inflammatory therapies. Inventors named include Mohamed M. Abdelghafour, Diána Szabó, László Janovák, Imre Dékány, and László Rovó. No compliance obligations or deadlines are imposed by this publication; it is informational in nature.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
SELF-ASSEMBLED MUCOADHESIVE BIOPOLYMER PARTICLE RELEASE SYSTEM AND PREPARATION METHOD THEREOF
Application US20260108615A1 Kind: A1 Apr 23, 2026
Inventors
Mohamed M ABDELGHAFOUR, Diána SZABÓ, László JANOVÁK, Imre DÉKÁNY, László ROVÓ
Abstract
The present invention relates to a mucoadhesive polymeric prodrug comprising a partially succinated polyvinyl alcohol (PVA-SA) with adjusted amount of hydroxyl and carboxyl pendant groups, which form an ester and/or amide linkage with amino and/or carboxyl and/or hydroxyl groups of biologically active compounds such as proteins, peptides, synthetic chemical, or natural products compounds (e.g. doxorubicin as an antitumor agent and antifibrotic drug). Preferably, said biologically active compounds are cysteamine (CYS) as the aminothiol compound and one compound selected from the group consisting of doxorubicin (DOX), ketoprofen (KETO), or 4-hydroxybenzyl alcohol (HBA). Moreover, the simultaneous presence of both hydroxyl and carboxyl groups in the partially succinated polyvinyl alcohol (PVA-SA) chain of the prodrug enables the self-assembled formation of 50-260 nm particles from the linear macromolecules and thus the drug release can be prolonged or adjusted. The present invention also relates to improving the mucoadhesive properties of the polymeric prodrug by the regulation of the amount of conjugated aminothiol compound. Further, the present invention relates to the method for producing said mucoadhesive polymeric prodrug, and nanoparticles of the said mucoadhesive polymeric prodrug.
CPC Classifications
A61K 47/58 A61K 9/006 A61K 9/5192 A61K 31/05 A61K 31/145 A61K 31/192 A61K 31/704 A61K 47/6937 B82Y 5/00 B82Y 40/00
Filing Date
2022-09-29
Application No.
18697611
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.